Connect

Member Research and Reports

Member Research and Reports

SUNY Downstate: Faculty-Led Landmark Drug Trial Finds Reduction of Heart Attack and Stroke in 18K High-Risk Patients in 57 Countries

In a large international clinical trial (ODYSSEY OUTCOMES) involving 18,924 patients from 57 countries who had suffered a recent heart attack or threatened heart attack, researchers and scientists around the world, including Dr. Michael Szarek, chair and professor of the Department of Epidemiology & Biostatistics at the SUNY Downstate Medical Center School of Public Health, have found that the cholesterol-lowering drug alirocumab reduced the chance of having additional heart problems or stroke in these high-risk patients.

Read more about the ODYSSEY OUTCOMES study.

At the American College of Cardiology Conference (ACC) last week, Dr. Szarek moderated a poster presentation and co-authored three oral presentations, one of which discussed the ODYSSEY OUTCOMES study shared above.

View detailed ACC presentation slides.

Tags: